Study Results
Three randomized placebo-controlled trials, published in peer-reviewed journals (Cognition & Longevity). One randomized, placebo controlled study (REM Sleep) and one randomized, placebo-controlled clinical trial (Peptide)
IgniCognition™ · Cognitive Study
In a 90-day randomized, placebo-controlled university study, participants taking the enhanced IgniCognition™ formula showed statistically significant improvements across every cognitive measure — beginning at the first 30-day measurement and continuing.**
+28%
Improvement in Short Term Memory**
vs. baseline at day 30
+83%
Improvement in Mental Quality of Performance**
vs. baseline at day 30
+51%
Improvement in Attention**
vs. baseline at day 30
+25%
Improvement in Operational Memory**
vs. baseline at day 30
2
University Trials
Published in peer-reviewed journals
6
Memory Quizzes
On our website to measure it yourself
IgniCognition™ · Cognitive Study (Covid)
In a 60-day randomized, placebo-controlled university study, Both Covid and non-Covid participants taking the enhanced IgniCognition™ formula showed statistically significant improvements in Short Term Memory and in Attention.**
+33%
Improvement in Short Term Memory**
Total Avg
+46%
Improvement in Short Term Memory**
Covid Group Avg
+67%
Improvement in Attention**
Total Avg
+70%
Improvement in Attention**
Covid Group Avg
Published research on the individual ingredients in this product. Studies are grouped by ingredient and link to the underlying publication record.
| Published study | Journal | Year | Relevance |
|---|---|---|---|
| Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | The Journal of Nutrition | 2021 | Randomized double-blind placebo-controlled trial; 100 adults aged 50-85; 500 mg/day for 12 weeks. |
| Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion | Methods and Findings in Experimental and Clinical Pharmacology | 2000 | Randomized double-blind placebo-controlled clinical trial in mild-to-moderate Alzheimer disease. |
Search PubMed for additional Citicoline (CDP-choline) research
| Published study | Journal | Year | Relevance |
|---|---|---|---|
| Efficacy and safety of choline alphoscerate for amnestic mild cognitive impairment: a randomized double-blind placebo-controlled trial | Alzheimer's Research & Therapy | 2024 | Multicenter randomized placebo-controlled trial; 100 participants with mild cognitive impairment; 600 mg alpha-GPC for 12 weeks. |
| Published study | Journal | Year | Relevance |
|---|---|---|---|
| The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial | Journal of Human Nutrition and Dietetics | 2014 | Randomized double-blind placebo-controlled trial; soy-derived phosphatidylserine 200 mg/day for 2 months. |
A very large CoQ10 literature exists across cardiovascular, mitochondrial, neurologic and fatigue outcomes. The study listed below includes CoQ10 in combination with NADH; use the comprehensive PubMed link for the larger isolated-CoQ10 literature.
| Published study | Journal | Year | Relevance |
|---|---|---|---|
| Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial | Nutrients | 2021 | Randomized double-blind placebo-controlled trial of CoQ10 + NADH. Included because it directly studies CoQ10 but is not isolated-ingredient evidence. |
Search PubMed for additional Coenzyme Q10 (CoQ10; ubiquinone/ubiquinol literature) research
Human studies exist in fatigue, Parkinson disease and related contexts, but many are small or use combination products. Combination evidence is explicitly labeled.
| Published study | Journal | Year | Relevance |
|---|---|---|---|
| Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial | Nutrients | 2021 | Randomized double-blind placebo-controlled trial; 20 mg NADH + 200 mg CoQ10 daily. Combination evidence, not isolated NADH evidence. |
Search PubMed for additional NADH (reduced nicotinamide adenine dinucleotide) research
Direct human clinical literature on the N-acetyl derivative itself is sparse. Most performance-under-stress trials use L-tyrosine, which should not be treated as equivalent evidence for NALT without pharmacokinetic justification. No direct human clinical study was selected for the curated layer because the exact-ingredient evidence is sparse or not clearly separable from related compounds/formulations. Use the comprehensive PubMed link above for the full indexed literature.
No direct human clinical study was selected for the curated study table for this exact ingredient/form.
Search PubMed for additional N-Acetyl-L-Tyrosine (NALT) research
Research references are provided for educational and scientific context. Published studies on individual ingredients do not establish that this product will produce the same outcomes, and some cited studies use different doses, routes, populations, or combination formulations. Links open to PubMed records where available.
How Results build over time
Week 1-4
Most people start noticing something here. Mental clarity improves. This is your mitochondria waking up.
Month 1-2
This is where the studies showed those numbers — Memory, Attention, Processing Speed are UP.** If you retake the Memory Quizzes, you can actually see this. Not just feel it. Measure it.
Month 3+
Epigenetic support is compounding. This is where the long game pays off — a greater sense of calm, control, and consciousness in daily life that builds every month you stay consistent.
